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Abstract 30 
Background: Signalling through the T cell receptor (TCR) is critical for T cell development and function. 31 
Linker for activation of T cells (LAT) is a transmembrane adaptor signalling molecule that is part of the 32 
TCR complex and is essential for T cell development as demonstrated by LAT-deficient mice which 33 
show a complete lack of peripheral T cells. 34 
Objective: We describe a pedigree affected by a severe combined immunodeficiency (SCID) phenotype 35 
with absent T cells and normal B cells and natural killer (NK) cells. A novel homozygous frameshift 36 
mutation in the gene encoding for LAT was identified in this kindred. 37 
Methods: Genetic, molecular and functional analyses were used to identify and characterise the LAT 38 
defect. Clinical and immunological analysis of patients was also performed and reported. 39 
Results: Homozygosity mapping was used to identify potential defective genes. Sanger sequencing of 40 
the LAT gene showed a mutation that resulted in a premature stop codon and protein truncation leading 41 
to complete loss-of-function and loss-of-expression of LAT in the affected family members. We also 42 
demonstrate loss of LAT expression and lack of TCR signalling restoration in LAT-deficient cell lines 43 
reconstituted with a synthetic LAT gene bearing this SCID mutation. 44 
Conclusion: The results of this study shows for the first time that inherited LAT deficiency should be 45 
considered in patients with combined immunodeficiency with T cell abnormalities. 46 
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Clinical implications: 48 
Mutations in LAT can lead to severe combined immunodeficiency and LAT should be part of the genetic 49 
diagnostic work up in SCID patients. 50 
 51 
Capsule Summary: 52 
Severe combined immunodeficiency can arise from a number of different genetic causes. Here, we show 53 
that mutations in LAT can lead to SCID and highlight the critical role of LAT in TCR signalling in T cell 54 
development. 55 
 56 
Key words: SCID, LAT, Immunodeficiency, T cell receptor signalling, Genetic defect, T lymphopenia 57 
 58 
Abbreviations used 59 
B: B lymphocyte 60 
FACS: Fluorescence-activated cell sorting 61 
GFP: Green fluorescent protein 62 
LAT: Linker for activation of T cells 63 
MOI: Multiplicity of infection 64 
NK: Natural killer cell 65 
OMIM: Online Mendelian inheritance in man 66 
PBMCs: Peripheral blood mononuclear cells 67 
PCR: Polymerase chain reaction 68 
PHA: Phytohaemagglutinin 69 
SCID: Severe combined immunodeficiency 70 
SNP: Single nucleotide polymorphism 71 
STRs: Short tandem repeats 72 
T: T lymphocyte 73 
TCR: T cell receptor 74 
Introduction 75 
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T cell receptor (TCR) signalling is an essential process, both for the development of T cells and also for 76 
their activation and function in the periphery. During thymic development, TCR engagement leads to the 77 
phosphorylation of the immunoreceptor tyrosine-based activation motifs (ITAMs) located in the 78 
cytoplasmic tails of TCR associated subunits, through the action of Src family kinases such as Lck and 79 
Fyn. This in turn leads to the recruitment and subsequent activation of the ZAP-70 (chain associated 80 
protein tyrosine kinase of 70 kDa) kinase which then phosphorylates specific residues on the TCR 81 
adaptor protein (TRAP), LAT (Linker for activation of T cells)1. Although it has no intrinsic enzymatic 82 
activity, LAT performs a critical function in TCR signal transduction by acting as a scaffold protein and 83 
coupling the TCR to downstream signalling pathways through enzyme activation and second 84 
messengers including calcium influx through recruitment of other factors and playing an essential role in 85 
intracellular Ca2+ mobilization, optimal tyrosine phosphorylation of PLC-γ1, Vav and SLP-76, Erk 86 
activation, CD69 up-regulation, AP- and NFAT-mediated gene transcription2,3 and apoptosis4,5. 87 
 88 
Severe combined immunodeficiencies (SCIDs) are a group of immunological disorders that arise from a 89 
variety of monogenic defects that lead to an absence of lymphocyte development and function. Overall 90 
incidence is estimated to be approximately 1 per 50000 live births and patients with SCID do not survive 91 
beyond the first year of life unless immunity can be restored6. SCIDs are typically characterized by the 92 
abrogation of adaptive immunity and specifically by a low number of autologous T cells (< 300 93 
cells/mm3). The absence of mature T lymphocytes and B cell dysfunction commonly leads to lethal 94 
complications such as opportunistic and non-opportunistic infections, chronic diarrhoea and failure to 95 
thrive7. 96 
 97 
A number of genetic basis defects in the TCR signalling pathway have now been shown to lead to a 98 
SCID or a less severe CID (combined immunodeficiency – in which there is greater T cell development 99 
albeit often with abnormal function) phenotype. This includes mutations in the CD3 subunits (CD3δ, 100 
CD3ε, CD3ζ), CD45, and ZAP-70, interleukin-2 inducible T cell kinase (ITK), ORAI calcium release-101 
activated calcium modulator 1 (ORAI-1), stromal interaction molecule 1 (STIM1), magnesium transporter 102 
1 (MAGT1) and LCK8. 103 
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 104 
LAT has not previously been associated with a human disease, although it has always been considered 105 
a strong candidate for SCID especially since LAT-deficient mice have severe defects in T cell 106 
development but normal B cell and NK cell populations9. Here we report for the first time 5 patients of a 107 
multi-generation consanguineous Pakistani family with a well defined SCID immunophenotype (T-B+NK+ 108 
SCID) caused by a frameshift mutation in LAT. 109 
110 
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Methods 111 
Study approval 112 
Genetics studies approved by the UCL Institute of Child Health Research Ethics Committee. Written 113 
informed consent was obtained from the patients’ parents. 114 
 115 
Genomic studies 116 
Genomic DNA from patients and their relatives was extracted from blood according to standard methods 117 
(QIAamp DNA mini kit, QIAGEN). Genotypes from DNA of three affected children (V.1, V.12 and V.13), 118 
their parents (IV.4, IV.5, IV.11 and IV.12) and four unaffected siblings (V.9, V.10, V.11, V.14) was 119 
generated with the single nucleotide polymorphisms (SNP) chip arrays (GeneChip Human Mapping 120 
250K Sty, Affymetrix) according to manufacturer’s instructions. Haplotype analysis and homozygosity 121 
mapping was done using IBDFinder10. Oligonucleotide primers flanking the exons of LAT (CCDS 10647) 122 
and CORO1A encompassing splice sites were used for the polymerase chain reaction (PCR) 123 
experiments. Primer sequences are listed in supplementary Table I. PCR products were amplified with 124 
the use of Qiagen HotStar Taq DNA polymerase, purified using ethanol/EDTA precipitation and Sanger 125 
sequenced with Big Dye v1 (Applied Biosystems) using the forward and reverse primers used for PCR. 126 
Sequence alignments were performed and visualised using Sequencher DNA sequencing assembly and 127 
analysis software (Genecodes). Single nucleotide polymorphisms (SNP) searches were performed in the 128 
National Council for Biotechnology Information dbSNP database (http://www.ncbi.nlm.nih.gov/SNP), the 129 
1000 Genomes project (http://browser.1000genomes.org), the Exome Sequence Project’s Exome 130 
Variant Server (http://evs.gs.washington.edu/EVS) and Exome Aggregation Consortium (ExAC), 131 
Cambridge, MA (http://exac.broadinstitute.org) (December 2015). 132 
 133 
Cell culture 134 
The human leukemic Jurkat T cell line (JE6.1)11 and the derivative LAT-deficient cell lines, ANJ33 and 135 
J.CaM212,13, were maintained in RPMI 1640 (Gibco) supplemented with 10% FCS (Sigma) and 10µg/ml 136 
each of penicillin and streptomycin (Gibco), and cultured at 37°C, 5% CO 2. 137 
 138 
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Immunoprecipitation, Western blot and antibodies 139 
For immunoprecipitation, Jurkat T cells were grown up to a density of 1x106/ml, centrifuged, and serum-140 
starved in RPMI 1640 with 0.1% FCS for 15-20h14. Then, about 1x108 cells were either stimulated with 141 
anti-CD3ε antibody (OKT3, BioLegend, 50µg/108 cells/ml PBS) for 2min at 37°C, or left untreated.  Cells 142 
were lysed in 2ml of ice-cold lysis buffer containing 1% Brij-97, 10mM Tris (pH7.6), 150mM NaCl, 2mM 143 
EDTA, and a cocktail of protease and phosphatase inhibitors (1X)3. Proteins of interest were then 144 
immunoprecipitated using the Dynabeads Protein G Immunoprecipitation kit (Novex, 10007D) according 145 
to the manufacturer’s instructions. 146 
For Western blot, protein samples were resolved on SDS-PAGE according to standard protocols, 147 
transferred to PVDF transfer membrane (Millipore) and immunoblotted with different antibodies. Protein 148 
loads were checked using rabbit anti-ACTIN antibody (Sigma, A2066). Immunoreactive proteins were 149 
detected with horseradish peroxidase-coupled secondary antibodies (GE Healthcare) followed by ECL 150 
(Thermo Scientific). 151 
The antibodies used in the experiments were: mouse monoclonal anti-Phosphotyrosine (clone 4G10, 152 
Millipore, 05-321), mouse monoclonal anti-LAT (abcam, ab57204), rabbit monoclonal anti-Vav proteins 153 
(EP482Y, abcam, ab40875), mouse purified anti-SLP-76 (BioLegend, 625002). 154 
 155 
Generation of c.44_45insT LAT gene-bearing lentiviral vector 156 
The insertion of a T between base 44 and 45 of the LAT gene was performed using the GENEART site-157 
directed mutagenesis system (Invitrogen) according to manufacturer's instruction. As a template for the 158 
mutagenesis we used a pMA plasmid bearing a synthetic copy of the human LAT gene 159 
(0957198_LAT_pMA, GENEART) (Suppl. Fig. 1 A). The mutagenesis reaction was performed using two 160 
overlapping primers containing the target mutation (Suppl. Fig. 1 C) and the correct insertion of a T 161 
between base 44 and 45 of LAT was verified by sequencing as shown in Suppl. Fig. 1 D and E. The 162 
mutant copy of LAT gene was then excised and cloned into a Lent_SF_Ires_GFP_C427 vector 163 
(0957199_LAT_Lent_SF_Ires_GFP, GENEART) (Suppl. Fig. 1 B) using BamHI cloning sites. The 164 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 9 
Lent_SF_Ires_GFP_C427 vector bearing either the wild-type or the mutant copy of the LAT gene was 165 
then used to generate lentiviruses by transfecting 293T cells. 166 
 167 
Lentivirus production 168 
Both the lentiviral vector bearing a wild-type copy of LAT gene (0957199_LAT_Lent_SF_Ires_GFP, 169 
GENEART, Suppl. Fig. 1 B) hereafter called as wtLAT-GFP-lent, and the one bearing the mutated copy 170 
of LAT hereafter as mutLAT-GFP-lent, were used for producing lentivirus according to previously 171 
described protocol15. Briefly, lentiviral particles were produced by transient co-transfection of 293T cells 172 
in 16cm Petri dishes with 10ml Opti-MEM medium (Gibco) containing 50µg of the corresponding lentiviral 173 
construct, 17.5µg and 32.5µg of packaging plasmids pMD.G2 (VSVG envelope) and pCMVdR8.74 (gag-174 
pol plasmid) (PlasmidFactory), respectively, using 1µl of 10mM polyethylenimine, for 4h at 37°C, 5% 175 
CO2. Cells were then washed and incubated with 18ml DMEM medium (Gibco) at 37°C, 5% CO 2. The 176 
virus particles were harvested 48 and 72 hours after transfection, cleared of cell debris by low-speed 177 
centrifugation and filtered using 0.45mm Stericup filters (Millipore). The lentivirus supernatant was then 178 
ultracentrifuged at 50000g, 4°C for 2h and the pell et resuspended in Opti-MEM and stored at -80°C. 179 
Virus titres (virus particles per ml concentrated aliquot) were determined in 293T cells transduced with 180 
serially diluted lentivirus aliquots by flow cytometry to measure the GFP expression. 181 
 182 
Lentiviral transduction of LAT-deficient Jurkat T cell lines 183 
Both ANJ3 and J.CaM2 cells (2.5x105 cells per well) were covered with 0.4ml medium (RPMI 1640, 10% 184 
FCS, 1X Pen/Strep) containing either wtLAT-GFP-lent or mutLAT-GFP-lent lentivirus at MOI 10 185 
[lentivirus particles per cell]. After 24h incubation at 37°C and 5% CO 2, the supernatant was exchanged 186 
to fresh medium and incubated for additional 24h. Cells were then kept in culture for expansion of cell 187 
number. 188 
 189 
Cytofluorimetric analysis 190 
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Following lentiviral transduction, cells were harvested at interval of 6 days, washed, resuspended in PBS 191 
and checked for the expression of GFP using a FACSCalibur (BD Biosciences) to quantify the 192 
percentage of transduced cells. 193 
 194 
Analysis of CD69 expression 195 
Jurkat T cells were either left untreated or stimulated with immobilised anti-CD3ε antibody (OKT3, 196 
BioLegend) ON at 37°C. A 24-well-plate was firstly coated with 2µg/ml OKT3 for 1 hour at 37°C, washed 197 
and about 1x106 of cells were plated per well for stimulation. Cells were then stained with APC-198 
conjugated anti-CD69 antibody (Miltenyi), washed and analyzed by FACSCalibur (BD Biosciences). 199 
 200 
Intracellular Ca2+ flux measurement 201 
The measurement for intracellular free Ca2+ was performed as described previously16. Briefly, Jurkat T 202 
cells were harvested from growth medium and 1x106 cells were resuspended in 1ml PBS, 0.5% BSA 203 
containing 5µg/ml Indo-1 (Invitrogen) and stained for 30min at 37°C. Cells were then washed and 204 
additionally incubated in PBS, 0.5% BSA containing 1mM Ca2+ and 1mM Mg2+. Cells were kept on ice 205 
before equilibration at 37°C for 5min directly befo re measurement. Changes in intracellular calcium were 206 
monitored using a flow cytometer LSRII (BD Biosciences). Indo-1 is excited by the UV-laser, its emission 207 
depends on whether it is bound to calcium (~420nm) or free (~510nm). The ratio of these two 208 
wavelengths indicates changes in intracellular calcium concentration. After monitoring the baseline 209 
activity for 30sec, the cells were stimulated either with 10µg/ml anti-CD3ε antibody (OKT3, BioLegend) 210 
or 10µg/ml ionomycin (Calbiochem) and calcium flux measured for additional 3.30 min. The kinetics of 211 
the data acquired were analysed using FlowJo 7.2.2 software (TreeStar). 212 
 213 
Apoptosis assay 214 
Jurkat T cells were stimulated with immobilized anti-CD3ε antibody (OKT3, BioLegend) ON at 37°C. A 215 
24-well-plate was firstly coated with 10µg/ml OKT3 ON at 4°C, washed and 0.5-1x10 6 cells were plated 216 
per well for stimulation. Cells were then stained with anti-human CD95 (APO-1/Fas, eBioscience), anti-217 
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human CD178 (Fas Ligand, TONBO biosciences) and with Annexin V Apoptosis Detection Kit APC 218 
according to manufacturer instructions (eBioscience), and analysed by FACSCalibur (BD Biosciences). 219 
 220 
  221 
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Results 222 
Clinical outcomes of the study patients 223 
We describe a multi-generation consanguineous Pakistani family with five patients affected by an 224 
autosomal recessive T-B+NK+ form of severe combined immunodeficiency (SCID) (Fig 1 A and Table I). 225 
Both male and female patients were born to two sets of first cousin parents within the same family. 226 
Patients V.1 and V.12 presented within the first three months of life with severe recurrent infections and 227 
failure to thrive and V.3, V.4 and V.13 were diagnosed at birth as a result of previous family history. T 228 
cell numbers were low (<300 cells/mm3) with absent proliferation response to PHA as might be expected 229 
in patients with such low T cell numbers, but B and NK cell numbers were normal. No NK cell functional 230 
analysis was performed. In one patient, V.1, the total number of T, B and NK cells did not equate to the 231 
total lymphocyte count. One possible explanation is that the T cell analysis performed was specifically for 232 
T cells bearing α/β receptors only and it is possible that there was a significant γ/δ TCR population which 233 
can be seen in cases of dysregulation of T cell development, although this was not specifically looked 234 
for. Immunoglobulin levels were evaluated soon after birth in three individuals, V.3, V.4 and V.13. IgG 235 
was present most probably as a result of maternal transfer, IgA was below the level of detection and IgM 236 
levels were at the very low end of the normal range.  IL7R alpha and CD3 subunits defects were 237 
considered unlikely due to haplotype analysis with microsatellite markers (STRs) and SNP arrays (data 238 
not shown). Also, no mutations were found in IL7R alpha by Sanger sequencing of all exons. Gamma 239 
chain expression was normal. All affected individuals underwent bone marrow transplant but three 240 
individuals V.1, V.3 and V.13 died due to transplant related complications. 241 
 242 
Genetic studies 243 
Genomic DNA was available for three affected individuals (V.1, V.12 and V.13), their unaffected parents 244 
(IV.4, IV.5, IV.11 and IV.12) and four unaffected siblings (V.9, V.10, V.11, V.14) for single nucleotide 245 
polymorphism (SNP) arrays. Haplotype analysis and homozygosity mapping in the family suggested that 246 
the disease gene localises to a 23.48 Mb region on chromosome 16 flanked by markers rs4787441 and 247 
rs10852513. Two genes within the region were prioritised based on information available in the literature 248 
and OMIM. Coronin Actin Binding Protein1A (CORO1A; MIM *605000) was selected as a strong 249 
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candidate for its causative involvement in immunodeficiency 8 (MIM #615401) characterised by recurrent 250 
infections and decreased number of lymphocytes but no causative variants were identified. Linker for 251 
activation of T cells (LAT; MIM *602354) also co-localized to this region and on sequencing of LAT 252 
coding regions in the family, we found all patients were homozygous for a recessive frameshift mutation 253 
in LAT exon 1 and both sets of parents were heterozygous for this variant (Fig 1 A and 1 B). As 254 
demonstrated in Fig 1 C, exon 1 is highly conserved across multiple vertebrate species. An insertion of a 255 
T between positions 44 and 45 in the coding sequence causes a frameshift and a putative stop codon 28 256 
amino acids downstream (c.44_45insT; p.Leu16AlafsX28). The nucleotide insertion was not recorded in 257 
publically available databases NCBI dbSNP, 1000 Genomes Project, the Exome Sequence Project’s 258 
Exome Variant Server or the Exome Aggregation Consortium (ExAC). To exclude the possibility of the 259 
insertion being a rare polymorphism present in the Pakistani population, genomic DNA from 150 260 
ethnically matched controls representative of a total of 300 chromosomes were also sequenced and 261 
found to be wild-type for the insertion (data not shown). A further 15 SCID patients were sequenced but 262 
failed to reveal any pathogenic variants in LAT. 263 
 264 
The variant results in a predicted truncation of the LAT protein. LAT is known to be expressed in 265 
peripheral blood lymphocytes, spleen and thymus, as well as in other blood cell types, notably platelets, 266 
megakaryocytes, mast cells and natural killer cells17. We therefore performed Western blot analysis for 267 
the expression of LAT in peripheral blood mononuclear cells (PBMCs) from patient V.4 and from a 268 
control blood sample (Fig 1 D). To control for the lack of T cells in the patient sample, control PBMCs 269 
were further processed for isolation of CD3 positive (CD3+) and negative (CD3-) cells. For each sample 270 
lysate from 5×106 cells was loaded in the gel. 293T cells and HeLa cells were also used as negative 271 
controls. As shown, even in control CD3- cells, LAT can be detected whereas it is not detectable in the 272 
patient PBMCs. It is likely that, because the premature termination codon is close to the 5’-end of the 273 
protein there is non-sense mediated decay and complete loss of protein expression. 274 
 275 
Reconstitution of LAT-deficient Jurkat T cell lines 276 
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The absence of primary patient material led us to perform in vitro studies to demonstrate the functional 277 
effect of the observed LAT mutation. We generated a synthetic mutant copy of human LAT by site-278 
directed mutagenesis and generated lentiviruses bearing wild-type (wtLAT-GFP-lent) or mutant (mutLAT-279 
GFP-lent) LAT. We then used both LAT-encoding lentiviruses to transduce two different Jurkat-derived 280 
TCR-signalling mutants2 both lacking expression of LAT gene, ANJ33 and J.CaM212,13,18 (Fig 2 A). The 281 
efficiency of transduction was evaluated by FACS analysis of the green fluorescent protein (GFP) 282 
expressed by the lentiviral vectors. One month after transduction, the percentage of GFP-positive cells 283 
were more than 85% in all the four cultured clones, ANJ3 and J.CaM2 transduced by either wtLAT-GFP-284 
lent (hereafter as ANJ3/wtLAT-GFP-lent and J.CaM2/wtLAT-GFP-lent) (Fig 2 B, upper panel) or 285 
mutLAT-GFP-lent (hereafter as ANJ3/mutLAT-GFP-lent and J.CaM2/mutLAT-GFP-lent) (Fig 2 B, lower 286 
panel) lentivirus. As expected, both ANJ3/wtLAT-GFP-lent and J.CaM2/wtLAT-GFP-lent clones also 287 
efficiently expressed LAT. On the contrary, the two clones transduced with the lentiviruses bearing the 288 
frameshift mutation in the LAT gene, ANJ3/mutLAT-GFP-lent and J.CaM2/mutLAT-GFP-lent were not 289 
able to express LAT as demonstrated by the Western-blot (Fig 2 A). Taken together these data 290 
confirmed the lentiviral vector efficacy in mediating gene transfer and expression in Jurkat T cell lines 291 
and confirmed in an in vitro system that the insertion of a T between base 44 and 45 of the LAT gene 292 
prevents its expression. 293 
 294 
CD69 up-regulation and intracellular Ca2+ mobilization after TCR stimulation 295 
CD69 is a marker for T cell activation and its expression is rapidly induced in a Ras-dependent manner 296 
following TCR stimulation in Jurkat T cells and easily detectable by FACS analysis19. Stimulation with the 297 
anti-CD3ε antibody OKT3 induced CD69 up-regulation in JE6.1 control cells, but failed to induce CD69 298 
expression in ANJ3 and J.CaM2 cells as shown in Fig 2 C (upper panel) and as previously reported3,18. 299 
To confirm that the failure of CD69 up-regulation was due to loss of LAT, both ANJ3 and J.CaM2 cells 300 
were transduced with a lentivirus containing a copy of the LAT gene (wtLAT-GFP-lent) as described 301 
above. Stably transduced cell lines reconstituted with wild-type LAT, ANJ3/wtLAT-GFP-lent and 302 
J.CaM2/wtLAT-GFP-lent, showed restored expression of CD69 on the cell surface following anti-CD3ε 303 
antibody stimulation (Fig 2 C, middle panel). On the contrary, cell lines ANJ3/mutLAT-GFP-lent and 304 
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J.CaM2/mutLAT-GFP-lent reconstituted with 44_45insT LAT , failed to restore full CD69 expression 305 
following TCR signalling stimulation with OKT3 (Fig 2 C, lower panel). 306 
Stimulation of TCR signalling with OKT3 also failed to induce Ca2+ mobilization in both LAT-deficient 307 
Jurkat T cell lines, ANJ3 (Fig 2 D, upper panel) and J.CaM2 (Suppl Fig 2 A, upper panel) as previously 308 
reported3,18. Similarly, LAT-deficient Jurkat T cell lines reconstituted with the mutant copy of LAT, 309 
ANJ3/mutLAT-GFP-lent and J.CaM2/mutLAT-GFP-lent, failed to induce calcium flux following OKT3 310 
stimulation (Fig 2 D and Suppl Fig 2 A, lower panels). On the contrary, control JE6.1 (Fig 2 D, upper 311 
panel) and wild-type LAT reconstituted cells, ANJ3/wtLAT-GFP-lent and J.CaM2/wtLAT-GFP-lent (Fig 2 312 
D and Suppl Fig 2 A, middle panels) showed a clear Ca2+ mobilization response to anti-CD3ε antibody 313 
stimulation. As expected, all Jurkat T cell lines, despite expression or not of LAT, were able to increase 314 
intracellular calcium levels following stimulation with ionomycin, a pharmacological agent which 315 
mobilizes intracellular calcium in a TCR-independent manner (Suppl Fig 2 B). 316 
Altogether these results show that re-expression of LAT in ANJ3 and J.CaM2 following lentivirus 317 
transduction, restore TCR signalling, confirming the pivotal role of LAT in T cell activation. The mutant 318 
LAT in the described SCID patients is not able to restore these functions. 319 
 320 
Mutant LAT reconstitution does not restore the tyrosine phosphorylation on downstream Vav 321 
and SLP-76. 322 
A clear role for LAT in regulating tyrosine phosphorylation of intracellular proteins during TCR 323 
engagement has already been shown3. Thus, to confirm optimal restoration of TCR signalling in ANJ3 324 
and J.CaM2 lines reconstituted with wild-type LAT, cells were stimulated with OKT3 and tyrosine 325 
phosphorylation was detected by probing protein samples with anti-Phosphotyrosine antibody 4G10 (Fig 326 
3 and Suppl 3). The tyrosine phosphorylated LAT molecule was not detected in cellular lysates prepared 327 
from ANJ3 and ANJ3 cells reconstituted with mutant LAT (ANJ3/mutLAT-GFP-lent), but as expected was 328 
observed in ANJ3 reconstituted with wild-type LAT (ANJ3/wtLAT-GFP-lent) (Fig 3 A). Importantly, 329 
reconstitution of wild-type LAT in ANJ3 and J.CaM2 cells restored the tyrosine phosphorylation of two 330 
proteins downstream LAT, Vav and SLP-76, that are involved in the signal transduction cascade initiated 331 
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by engagement of the TCR2. Tyrosine phosphorylation of these proteins was absent in protein samples 332 
from stimulated ANJ3, J.CaM2 and cell lines reconstituted with mutant LAT (Fig 3 B and C, and Suppl 3). 333 
 334 
Absence of LAT prevents TCR-induced apoptosis and is not restored by mutant LAT 335 
Upon TCR cross-linking, a number of studies have shown that LAT can be a negative regulator of TCR 336 
signalling, including mutant LAT knock-in models which show a T lymphoproliferative disease5,20-22. We 337 
stimulated JE6.1 and LAT-deficient ANJ3 and J.CaM2 cell lines with immobilized OKT3 and showed that 338 
there was significantly reduced apoptosis in mutant lines than in JE6.1 control cells (Fig 4 A and B). In 339 
reconstituted lines, introduction of wild type LAT in ANJ3/wtLAT-GFP-lent and J.CaM2/wtLAT-GFP-lent 340 
led to a significant increase in the level of apoptosis after T cell receptor stimulation whereas LAT-341 
deficient lines transduced with mutant LAT, ANJ3/mutLAT-GFP-lent and J.CaM2/mutLAT-GFP-lent, did 342 
not show any increase in levels of apoptosis (Fig 4 C and D). The expression levels of death factors 343 
such as Fas and Fas ligand4,23-27 (FasL) in ANJ3 and J.CaM2 lines were similar to that observed in the 344 
wild type Jurkat line JE6.1 (Suppl Fig 4). These studies support suggestions that TCR stimulation leads 345 
to T cell apoptosis that is dependent on functional LAT expression and that expression of the mutant 346 
LAT in LAT-deficient lines does not restore apoptosis whereas wild type LAT is able to restore apoptosis. 347 
  348 
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Discussion 349 
Genetic and molecular studies of SCIDs have led to the identification of mutations in many different 350 
genes that impair T lymphocyte differentiation and result in the clinical and immunological phenotype of 351 
SCID. A number of different mechanisms have been identified including: i) lymphocyte cell death 352 
triggered by purine metabolism abnormalities, ii) defective signalling through the common γ-chain-353 
dependent cytokine receptors, iii) defective V(D)J recombination and iv) defective pre-TCR/TCR 354 
signalling28. Mutations in key proteins involved in pre-TCR/TCR signalling are indeed responsible for rare 355 
cases of SCID consisting of pure T-cell deficiencies. These defects account for about 2% of individuals 356 
with SCID. Patients with defects in the hematopoietic-specific transmembrane protein tyrosine 357 
phosphatase CD45, required for efficient lymphocyte signalling, are severely immunodeficient and have 358 
very few peripheral T lymphocytes unresponsive to mitogen stimulation29,30. Similarly, deficiency of 359 
CD3ε31-34, CD3δ33,35,36 and CD3ζ37-40 subunits of the pre-TCR/TCR signalling complex cause near 360 
complete arrest of T-cell development and severe immunodeficiency. Further downstream, defects in 361 
ZAP-70, interleukin-2 inducible T cell kinase (ITK), ORAI calcium release-activated calcium modulator 1 362 
(ORAI-1), stromal interaction molecule 1 (STIM1), magnesium transporter 1 (MAGT1) and LCK have 363 
been reported but the immunophenotype in these individuals shows evidence of T cell development 364 
although these T cells are abnormal and in some cases associated with severe immune-dysregulatory 365 
phenomena8. This report documents the first cases of LAT deficiency in a multi-generation 366 
consanguineous Pakistani family due to an insertion of a T between positions 44 and 45 in the coding 367 
sequence (c.44_45insT; p.Leu16AlafsX28) that causes a frameshift and a putative stop codon 28 amino 368 
acids downstream. The immunological phenotype in these individuals is characterized by a significant 369 
lack of T cell development and highlights the critical and non-redundant role of LAT in the regulation of T 370 
cell development. 371 
 372 
The human immunophenotype observed here is very similar to that observed in a murine knock-out 373 
model. In this model, there is a complete lack of peripheral T cells but LAT-deficient mice have normal B 374 
cell populations and no gross abnormality of NK numbers or function9. Further analysis of these mice 375 
shows that thymocyte development is arrested at the CD4-CD8- double negative (DN) stage and 376 
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CD4+CD8+ double positive (DP) and CD4+ or CD8+ single positive (SP) thymocytes were undetectable. 377 
More specifically, the arrest is at the CD25+CD44- DN3 stage and indicates the absolute requirement for 378 
LAT in the pre-TCR-mediated signal transduction that is required for further thymocyte development. The 379 
role of LAT beyond the DN3 stage has also been studied by the generation of LAT knock-in mice in 380 
which the LAT gene could be deleted upon expression of the Cre recombinase at later stages of 381 
thymocyte development41. These mice developed DP thymocytes but there was a significant block in the 382 
SP thymocytes and consequently a significant loss of mature peripheral T cells. In addition, there were 383 
abnormalities of Treg development and function which is also supported by other studies42. Together 384 
these murine studies highlight the essential role of LAT in early pre-TCR and later thymocyte 385 
development. 386 
 387 
Mechanistically, it has already been shown that upon stimulation of the TCR, LAT becomes 388 
phosphorylated at several tyrosines residues on its cytoplasmic tail. This leads to the binding of SH2 389 
domain-containing proteins and their associated molecules and the formation of large multiprotein 390 
complexes located at the plasma membrane43,44. These dynamic and highly regulated signalling 391 
complexes facilitate the production of second messengers, activate downstream pathways such as 392 
intracellular Ca2+ mobilization, induce actin cytoskeleton polymerization, and stimulate the activity of 393 
multiple transcription factors1,2. Thus, signalling pathways from the pre-TCR or TCR feed into LAT, which 394 
then integrates this information and selectively induces pathways critical for thymocyte development and 395 
T cell activation. In peripheral cells, there is evidence to suggest that LAT can also act as a negative 396 
regulator of TCR mediated signalling and that T cell apoptosis is dependent on a functional LAT protein. 397 
In the absence of LAT, there is reduced apoptosis, which in murine LAT mutant knock in models leads to 398 
lymphoproliferation5,20-22.  399 
 400 
In the absence of primary material (other than a limited source of PBMCs) from our patients who had 401 
either deceased or had undergone haematopoietic stem cell transplantation, we chose to demonstrate 402 
the non-functional effect of the patient mutation in specific cell lines. We used two LAT mutant Jurkat T 403 
cell lines, ANJ33 and J.CaM212,13, that are defective in TCR-mediated signal transduction. Although initial 404 
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TCR-mediated signalling events such as the inducible tyrosine phosphorylation of the CD3-ζ chain and 405 
ZAP-70 are intact, subsequent events, including phosphorylation of LAT downstream proteins such as 406 
SLP-76, Vav and PLCγ1, increases in intracellular Ca2+, Ras activation, CD69 upregulation and IL-2 407 
gene expression and apoptosis are defective in these mutant cell lines3,18. Through lentiviral gene 408 
transfer, we introduced either the wild-type or the observed mutant LAT gene into these mutant lines and 409 
determined the functional consequences. Both reconstituted cell lines that expressed wild-type LAT had 410 
levels comparable to that of Jurkat T cells (JE6.1) and all LAT downstream TCR-inducible signalling 411 
events were reconstituted. We also show failure to express LAT protein and loss of TCR-induced 412 
signalling and restoration of apoptosis in ANJ3 and J.CaM2 cells transduced by lentiviruses bearing a 413 
copy of LAT gene with the frameshift mutation. We thus confirmed in an in vitro system the loss of LAT 414 
expression as a consequence of an insertion of a T between positions 44 and 45 in the coding 415 
sequence. The frameshift and a putative stop codon 28 amino acids downstream resulted in a truncation 416 
of the LAT protein with complete loss of function. Needless to say, in cell lines in which the patient 417 
mutant LAT was expressed, there was no evidence of recovery of TCR downstream signalling events. 418 
We would therefore infer that there is a similar loss of pre-TCR and TCR signalling in these patients that 419 
would lead to and explain the lack of T cell development. 420 
 421 
This is the first report of LAT mutations leading to SCID. The genetic data is highly significant in that it 422 
shows the presence of a highly deleterious variant that, in both primary patient cells and after in vitro 423 
expression, leads to the absence of LAT protein expression. The mutation co-segregates with disease 424 
and is found in heterozygous form in unaffected carriers and family members. No evidence of this 425 
mutation was identified in a number of different human publically available databases. Importantly, when 426 
we studied 300 chromosomes from an ethnically-matched cohort, the mutation was not identified and 427 
demonstrates that this variant is not a polymorphism but is a founder mutation that is carried in this 428 
consanguineous pedigree. The expression of this mutant in LAT-deficient cells showed the absence of 429 
protein expression and an inability to reconstitute LAT specific signalling events. Together these data 430 
argue strongly that the LAT mutation identified leads to the SCID immunophenotype in this pedigree. 431 
 432 
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Although, many gene defects have been identified as causing SCID, recent data from prospective SCID 433 
screening studies show that there are still >10% of SCID patients that remain genetically undiagnosed6. 434 
It is likely that, as in this family, mutations in other genes already known from murine and other studies to 435 
be critical for T cell development, will be soon be identified. 436 
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Figure legend 445 
 446 
Figure 1. A frameshift mutation in LAT leads to loss of LAT expression in patients’ T cells. (A) 447 
Extended consanguineous pedigree. (B) Sequence analysis of genomic LAT in a control, unaffected 448 
heterozygous individual IV.5 and homozygous mutation in patient V.12 (C) LAT protein first 43 amino 449 
acids sequence showing frameshift and premature termination codon (*) in red letters in LAT exon 1 at 450 
position 43. Protein homology of LAT in various species (D) LAT expression in PBMCs from patient and 451 
control. 452 
 453 
Figure 2. Reconstitution of LAT-deficient Jurkat T cell lines. (A) Analysis of LAT expression in Jurkat 454 
T cell lines. (B) Lentiviral vector gene expression in reconstituted Jurkat T cell lines by FACS analysis of 455 
GFP. (C) CD69 expression in Jurkat T cell lines unstimulated (red line) or stimulated (green line) with 456 
OKT3. (D) Ca2+ mobilization in JE6.1 and ANJ3 cell lines unstimulated (control) or stimulated with OKT3.  457 
 458 
Figure 3. Tyrosine phosphorylation of LAT, Vav and SLP-76 in ANJ3 cell lines. (A) Cellular lysates 459 
from ANJ3 cell lines unstimulated (-) or OKT3-stimulated (+) were analysed by immunoblotting with anti-460 
Phosphotyrosine (pY), anti-LAT and anti-ACTIN. (B) Vav and (C) SLP-76 were immunoprecipitated from 461 
unstimulated (-) or OKT3-stimulated (+) ANJ3 cell lines with antibodies against each individual protein. 462 
Immunoprecipitates were then analysed by immunoblotting with anti-pY and antibodies against each 463 
individual protein. 464 
 465 
Figure 4. Apoptosis assay on Jurkat T cell lines. (A) Jurkat T cell lines were stimulated with OKT3, 466 
then stained with Annexin V and propidium iodate (PI) and analysed by FACS. Percentages of early 467 
stage apoptotic cells (Annexin V+/PI-) are plotted in (B), (C) and (D). P-values for statistical significance 468 
are indicated as (*) p ≤ 0.05, (**) p ≤ 0.01 and (***) p ≤ 0.001. 469 
 470 
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Patient 
 
P V.1 P V .3 P V.4 P V.12 P V.13 
Gender M F F F M 
Year of birth 2004 2009 2012 2000 2005 
Clinical presentation Recurrent 
infections 
Diagnosed at 
birth 
Diagnosed at 
birth 
Recurrent 
infection and 
failure to thrive 
Diagnosed at birth 
BMT donor and 
conditioning 
Parental 
haploidentical 
1
st
 BMT – 
unconditioned 
2
nd 
BMT – 
Melphalan only 
MUD 
Busulfan 
Fludarabine 
 
MUD MSD MSD  
unconditioned 
 
Outcome Died – multi-organ 
failure post 2
nd
 
BMT 
Died – cardiac 
arrest and multi-
organ failure 
following 
conditioning 
Alive and well Alive and well Died – severe 
acute and chronic 
GvHD and 
respiratory 
compromise 
Immunological features at presentation 
Absolute lymphocyte 
count (cells/mm
3
) 
900 960 1190 N/A* 2610 
CD3+ – T cells 
(cells/mm
3
) 
20 10 6 N/A* 300 
CD19+ – B cells 
(cells/mm
3
) 
620 440 428 N/A* 1440 
CD16+/CD56+ – NK 
cells (cells/mm
3
) 
140 450 666 N/A* 780 
CD3+CD4+ (cells/mm
3
) 10 0 4 N/A* 210 
CD3+CD8+ (cells/mm
3
) 0 0 0 N/A* 30 
PHA response (SI) 1.9 4.8 N/A N/A* 3.1 
IgG (g/l) 
**(normal 1 – 3.3) 
N/A 8.23 6.09 N/A* 6.8 
IgA (g/l) 
(normal 0.07 – 0.37) 
N/A <0.06 <0.07 N/A* <0.07 
IgM (g/l) 
(normal 0.26 – 1.22) 
N/A 0.28 0.20 N/A* 0.17 
 472 
*Presentation immunology not available as patient referred from remote hospital after transplantation had already 473 
been undertaken 474 
**normal ranges taken from the Mayo clinic reference range (http://www.mayomedicallaboratories.com/test-475 
catalog/Clinical+and+Interpretive/8156) 476 
 477 
MUD – matched unrelated donor transplant 478 
MSD – Matched sibling donor transplant 479 
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BMT – bone marrow transplantation 480 
SI – stimulation index 481 
N/A – not available 482 
 483 
 484 
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Supplementary Figure 1. Generation of 44_45insT LAT gene-bearing lentiviral 
vector. Map of (A) pMA plasmid bearing a synthetic copy of human LAT gene and of (B) 
lentiviral vector bearing GFP and LAT genes (GENEART). (C) The overlapping primers 
designed for the side-directed mutagenesis. DNA sequences of wild-type (D) and mutant 
(E) LAT gene-bearing lentiviral vectors at the site of the insertional mutagenesis. 
 
Supplementary Figure 2. Restoration of calcium flux in J.CaM2 cells and 
ionomycin-induced mobilization of calcium. Ca2+ mobilization in (A) J.Cam2 cell lines 
loaded with Indo-1 and stimulated with OKT3 or kept unstimulated (control) and in (B) 
Jurkat T cell lines loaded with Indo-1 and stimulated with ionomycin or kept unstimulated 
(control). The ratio of the fluorescence emission of Ca2+-bound and Ca2+-free Indo-1 was 
plotted as a function of time after stimulation. 
 
Supplementary Figure 3. Tyrosine phosphorylation of SLP-76 and Vav in J.CaM2 T 
cell lines. (A) Cellular lysates from JE6.1 and J.CaM2 cell lines unstimulated (-) or 
OKT3-stimulated (+) were analysed by immunoblotting with anti-Phosphotyrosine (pY), 
anti-SLP-76 and anti-ACTIN. (B) Vav was immunoprecipitated from unstimulated (-) or 
OKT3-stimulated (+) J.CaM2 cell lines with an antibody against Vav protein. 
Immunoprecipitates were then analysed by immunoblotting with anti-Phosphotyrosine 
(pY) and anti-Vav antibodies. 
 
Supplementary Figure 4. Expression analysis of death-factors Fas and FasL in 
Jurkat T cell lines. JE6.1 and LAT-deficient ANJ3 and J.CaM2 cell lines were 
unstimulated (green line) or stimulated  with OKT3 (blue line), then stained with 
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antibodies against CD95/Fas (A) or CD178/Fas Ligand (B) and with isotype controls 
(shaded areas). 
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A B
C
Homozygous patient V.12
insT
Leu Leu Leu Ala Ala His
Heterozygous IV.5
insT
c.44_45insT; p.Leu16AlafsX28
Leu Leu Leu Leu Pro Ile
Wild type control
Protein sequence
Wild type
p.Leu16AlafsX28
1 MEEAILVPCVLGLLLLPILAMLMALCVHCHRLPGSYDSTSSDS...
1 MEEAILVPCVLGLLLAAHPGHVDGTVCALPQTARLLRQHILR* 43
Human            MEEA-ILVPCVLGLLLLPILAML-MALCVHCHRLPGSYDSTSSDS
Mouse            MEAD-ALSPVGLGLLLLPFLVTLLAALCVRCRELPVSYDSTSTES
Pan            MEEA-ILVPCMLGLLLLPILAML-MALCVHCHRLPGSYDSTSSDS
Gorilla          MEEA-ILVPCVLGLLLLPILAML-MALCVHCHRLPGSYDSTSSDS
Rattus MEAD-ALSPVELGLLLLPFVVMLLAALCVRCRELPASYDSASTES
Felis MEAV-VLIPYVLGLLLLPLLA---VVLCVRCRKLPGFYDHTASDS
Canis MEAV-VLIPYMLGLLLLPLLA---VVLCVRCRELPGSYDSTASDS
Cavia MEENSVVLSEPLGLLLLPLIAMLLMVLCVRCRELRGSYGSASENR
Zebrafish MDSI-ELLSMVGGLLLLSIIFAT--GLCTYCWGHKQPTSIPQRPS
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Supplementary Table I. Primers used for PCR amplification and Sanger 
sequencing of genomic DNA of human CORO1A and LAT genes.  
Primer name Primer sequence Product size Tm 
CORO1A 
Exon 2F AGACTGAGGGGTGTCCTGG 362bp 60 Exon 2R CACCTAATCAGGACCTGCAC 
Exon 3-4F GCCTCTCTGAAGGAGGTGTG 448bp 60 Exon 3-4R AGTGTCAGAAGCCATGAGCC 
Exon 5-6F TCAGTGCAGGTGCTGCG 563bp 60 Exon 5-6R AGCAGGGACGAAACCTCC 
Exon 7-8F GTTGTTCCCACTGGTTGGTC 463bp 60 Exon 7-8R CTGGTTGGGTGGGCTTG 
Exon 9-10F ATGCTCCTTGGGCAGTGG 485bp 62 Exon 9-10R GATTCCCAATGTTGTGAGTTTG 
Exon 11F AGGGCTCTAGGGATGGGG 205bp 62 Exon 11R CATGTGGCTGGGAATGGG 
LAT 
Exon 1-2-3F TTCATCTGGCCTTGACTCTG 635bp 60 Exon 1-2-3R AAGGTGGCAGGGGAAGTC 
Exon 4-5-6F GCTTTCAGGGGCTTAGTCTG 596bp 60 Exon 4-5-6R GGTAACGACACAGGGGTCAG 
Exon 6-7F AGAACGAGGGTGCGTCTG 403bp 59 Exon 6-7R TACAATGGCACCACTGCAC 
Exon 8-9-10F CTCTGCATGGCTGAGGTTG 648bp 60 Exon 8-9-10R GGTCCTGGAGGGAAGGAG 
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